Cargando…
Tofacitinib in the treatment of patients with rheumatoid arthritis: position statement of experts of the Polish Society for Rheumatology
Tofacitinib is a newly approved small-molecule targeted synthetic disease-modifying antirheumatic drug. The drug was designed as a selective and specific inhibitor of pro-inflammatory receptor signalling. Tofacitinib inhibits the process of intracellular signalling from the receptor to the cellular...
Autores principales: | Kucharz, Eugeniusz J., Stajszczyk, Marcin, Kotulska-Kucharz, Anna, Batko, Bogdan, Brzosko, Marek, Jeka, Sławomir, Leszczyński, Piotr, Majdan, Maria, Olesińska, Marzena, Samborski, Włodzimierz, Wiland, Piotr |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6142023/ https://www.ncbi.nlm.nih.gov/pubmed/30237624 http://dx.doi.org/10.5114/reum.2018.77971 |
Ejemplares similares
-
Real-World Data from a Multi-Center Study: Insights to Psoriatic Arthritis Care
por: Batko, Bogdan, et al.
Publicado: (2021) -
Biosimilar switching – current state of knowledge
por: Wiland, Piotr, et al.
Publicado: (2018) -
Budget impact analysis and treatment availability with biosimilar TNF inhibitors in rheumatic diseases in Poland: real-world evidence using a nationwide database
por: Stajszczyk, Marcin, et al.
Publicado: (2023) -
Factors associated with quality of life in systemic sclerosis: a cross-sectional study
por: Sierakowska, Matylda, et al.
Publicado: (2019) -
Tumor necrosis factor alpha inhibitors and demyelinating disease: what is behind it?
por: Kucharz, Eugeniusz Józef, et al.
Publicado: (2021)